RIFERIMENTI BIBLIOGRAFICI

(1)

RIFERIMENTI BIBLIOGRAFICI

- Abi-Said D, Anaisse E, Uzun O, Raad I, Pinzcowski H, vartivarian

S. (1997). The epidemiology of ematogenous candidiasis caused by

different Candida species. Clin Infect Dis. 24:1122-8.

- Alexander B. D. et al. (2006). Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect. Dis. 43:S15-S27.

- Alvarez-Lerma F, Nolla-Salas J, Leon C, Palomar M, Jorda R,

Carrasco N & Bobillo F. (2003). Candiduria in critically ill patients

admitted to intensive care medical units. Intensive Care Med.

29:1069-1076.

- Antonella Lupetti, Arianna Tavanti, Paola Davini, Emilia

Ghelardi, Valerio Corsini, Ilaria Merusi, Antonio Boldrini, Mario Campa e Sonia Senesi. (2002). Horizontal Transmission of Candida

parapsilosis Candidemia in a Neonatal Intensive Care Unit. Journal

of Clinical Microbiology. 2363-2369.

- Antoniadou A, Torres HA, Lewis RE, et al. (2003). Candidemia in a tertiary care center: in vitro suscetipility and its association with out come of initial antifungal trerapy. Medicine (Baltimore). 82: 309-21.

- Arianna Tavanti, Amanda D. Davidson, Neil A. R. Gow, Martin C.

J. Maiden and Franck C. Odds (2005). Candida orthopsilosis and

Candida metapsilosis spp. nov. To Replace Candida parapsilosis

Groups

II

and

III

. Journal of clinical Microbiology. P:284-292.

- Asmundsdottir, L. R., H. Erlendsdottir, and M. Gottfredsson. (2002). Increasing incidence of candidemia: results from a 20-year nationwidw study in Iceland. J Clin. Microbiol. 40:3489-3492.

- Baillie, G. S., and L. J. Douglas. (1999). Role of dimorphism in the development of Candida albicans biofilm. J. med. Microbiol. 48:671-679.

(2)

Riferimenti Bibliografici, 90

- Baloch RI, Mercer EI. (1987). Inhibition of sterol D8-D7 isomerase and D14 reductase by fenpropimorph, tridemorph and fenprodpidin in cell free systems from Saccharomyces cerevisiae. Phytochemistry.

26: 663-68.

- Barrett-Bee K, Newboult L, Pander P. (1991). Biochemical changes associated with the antifungal action of the triazole ICI 153,066 on

Candida albicans and Trichophyton quinckeanum. FEMS Microbiol

Lett. 79: 127-32.

- Ben E. de Pauw. (2011). What are Fungal Infections? Mediterrean Journal of hematology and infectious diseases. 3; Open Journal System.

- Blinkhorn RJ, Adelstein D, Spagnuolo PJ (1989). Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol.

27: 236-240.

- Blot S, Vandewoude K. (2004). Management of invasive candidiasis in critically ill patients. Drugs. 64:2159-75.

- Bochud P-Y, Chien JW, Marr KA, Leisenring WM, Upton A, Janer

M, Rodrigues SD, Li S, Hansen JA, Zhao LP, Aderem A, Boeckh M. (2008). Toll-like receptor 4 polymorphisms and aspergillosis in

stem-cell transplantation. N Engl J Med. 359: 1766-1777.

- Bodey GP (1992) . Candidiasis. 2nd ed. Raven Press. pp1.

- Bolard J. (1986). How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta. 864: 257-304.

- Borman, A. M., C. J. Linton, D. Oliver, M. D. Palmer, A. Szekely,

F. C. Odds,and E. M. Johnson. (2009). Pyrosequencing analysis of

20 nucleotides of internal transcribed spacer 2 discriminates Candida

parapsilosis Candida, and Candida orthopsilosis. J. Clin. Microbiol.

47:2307–2310.

- Branchini, M. L., M. A. Pfaller, J. Rhine-Chalberg, T. Frempong,

and H. D. Isenberg. (1994). Genotypic variation and slime

production among blood and catheter isolates of Candida

parapsilosis. J. Clin. Microbiol. 32: 452-456.

- Calderone, A. (2002). Taxonomy and biology of Candida, p. 15-27.

In Candida and candidosis. ASM Press, American Society for

(3)

- Campa, D., Tavanti, A., Gemignani, F., Mogavero, C. S., Bellini,

I.,Bottari, F., Barale, R., Landi, S. & Senesi, S. (2008). DNA

microarraybased on arrayed-primer extension technique for identification of pathogenic fungi responsible for invasive and superficial mycoses. J Clin Microbiol. 46, 909–915.

- Carvalho A, Pasqualotto AC, Pitzurra L, Romani L, Denning DW,

Rodrigues F. (2008). Polymorphism in toll-like receptors genes and

susceptibility to pulmonary aspergillosis. J. Infect Dis. 197; 618-21.

- Chandra, J., P.K. Mukeherjee, S. D. Leidich, F. F. Faddoul, L. l.

Hoyer, L.J. Douglas, and M. A. Ghannoum. (2001). Antigungal

resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 80:903-908.

- Chen S, Tong Z, Lee O, Halliday C, Playford E, Widmer F, Kong

F, Wu C & Sorrell T. (2008). Clinician response to Candida

organism in the urine of patients attending hospitals. Eur J Clin MIcrobiol Infect Dis. 27:201-208.

- Chow Jk, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y,

Lichtenberg D, Chawla V, Young J, Hadley S. (2008). Factors

associated with candidemia caused by non-albicans Candida

species versus Candida albicans in the Intensive Care Unit. Clin

Infect Dis. 46:1206-1213.

- Cimolai N, Gill MJ, Church D (1987). Saccharomyces cerevisiae fungemia: a case report and review of the literature. Diagn Microbiol Infect Dis. 8: 113-117.

- Clark TA, Slavinski SA, Morgan J, et al. (2004). Epidemiologic and molecular Characterization o fan out break of Candida

parapsilosis bloodstreams infections in a community hospital. J Clin

Microbiol. 42:4468-72.

- Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoli T, Zarka D,

Clec’h C. (2010). Early prediction of Candida glabrata fungemia in

nonneutropenic critically ill patients. Crit Care Med. 38:826-830.

- Colombo AL, Guimaraes T, Silva LRBF, Monfardini LPDA,

Cunha AKB, Rady P, Alves T & Rosaa RC (2007). Prospective

Observational Study of Candidemia in Sao Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of mortality. Infec Control Hosp Epidemiol. 28:570-576.

(4)

- Dannaoui,E., Lortholary,O., Raoux,D., Bougnoux,M.E.,

Galeazzi,G., Lawrence,C., Moissenet,D., Poilane,I., Hoinard,D., Dromer,F., Bouges-Michel,C., Dunand,J., Bretagne,S.,

Fauchet,N., Forget,E., Botterel,F., Bonnal,C., Eloy,O., David,M.F., Mihaila,L., Chachaty,E., Adam,O., Chochillon,C., Paugam,A., Baixench,M.T., Cornet,M., Escande,M.C., Challier,S., Lavarde,V., Datry,A., Laklache,H., Lmimouni,B., Brun,S., Poirot,J.L.,

Lacroix,C., Develoux,M., & Bonacorsi,S. (2008). Comparative in

vitro activities of caspofungin and micafungin, determined using the method of the European committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005-2006.

Antimicrobial Agents and Chemotherapy. 52, 778-781.

- De Hoog GS, Guarro J, Gené J, Figueras MJ. (2000). Atlas of clinical fungi, 2nd ed., Centraalbureau voor schimmel culturesUniversitat Rovira i Virgili.

- Diana Pisa, Marta Ramos, Susana Molina, Patricia Garcıa´and

Luis Carrasco (2007) Evolution of antibody response and fungal

antigens in the serum of a patient infected with Candida famata. Journal of Medical Microbiology. 56, 571–578.

- Diekema DJ, Messer SA, Brueggemann AB, et al. (2002). Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organism Study. J Clin Microbiol. 40: 1298-302.

- Dimopoulous G, Ntziora F, Rachiotis G, Armaganidis A,

Falagas ME. (2008). Candida albicans versus non-albicans

intensive care unit-acquired bloodstreams infections:diggerences in risk factors and outcome. Anest Analg. 106:523-529.

- Dogra S, kumar B, Bhansali A, Chakrabartty A. (2002). Epidemiology of onychomycosis in patients dermatol. 41.647-51.

- Dromer F, Mathoulin-Pelissier S, Fontanet A, et al. (2004). Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS. 18:55-62.

- Dupont B, Denning DW, Marriott D, Sugar A, Viviani MA,

Sirisanthana T, Elewski., BE (1992). Cutaneous Fungal Infections.

(5)

- Eggimann P, Garbino J & Pittet D. (2003). Epidemiology of

Candida species infections in critically ill non.immunosuppressed

patients. Lancet Infect Dis. 3:685-702.

- Eschete ML, West BC. (1980). Saccharomyces cerevisiae septicaemia. Arch Inter Med. 140: 1539.

- Espinel-Ingroff, A., (2003). In vitro antifungal activities of

anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: Review of the literature. Rev. Iberoam. Micol.20: 121-136.

- Falagas ME, Roussos N, Vardakas KZ. (2010). Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. International Journal of Infectious Diseases.

- Fell, J. W. (1993). Rapid identification of yeast species using three primers in a polymerase chain reaction. Mol. Mar. Biol. Biotechnol.

2:174-180.

- French N, Gray K, Watera C, et al. (2002). Cryptococcal infection in a cohort of HIV-1 infected Ugandan adults. AIDS. 16:1031-8.

- Fromtling R. (1988). Overview of medically importan azole derivates. Clin Microbiol Rev. 1: 187-217.

- Fukuoka, T., D. A. Johnston, C. A. Winslow, M. J. deGroot, C.

Burt, C. A. Hitchcock, and S. G. Filler. (2003). Genetic basis for

differential activities of fluconazolo and voriconazole against

Candida krusei. Antimicrob. Agents Chemother. 47:1213-1219.

- Gallagher JJ, Williams-Bouyer N, Villarreal C, et al. (2007). Treatment of infection in burns. In Herndon DN, ed. Total Burn Care, 3rd edition. Philadelphia: WB Saunders:136-176.

- Gallis HA, Drew RH, Pichard WW. (1990). Amphotericin B: 30 years of clinical experience. Rev Infec Dis. 12: 308-329.

- Garcia-Effron G. Park S. Perlin D.S. (2009 ). Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother.

(6)

- Girmenia, C., G. Pizzarelli, F. Cristini, F. Barchiesi, E. Spreghini,

G. Scalise, and P. Martino (2006). Candida guilliermondii fungemia

in patients with ematologic malignancies. J Clin. Microbiol. 44:2458-2464.

- Goldman M, Cloud GA, Smedema M, et al. (2000). Does long-term itraconazolo prophylaxis result in in vitro azole resistance in mucosal

Candida albicans isolates from persons with advanced human

immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Antimicrob Agents Chemother. 44: 1585-7.

- Gomez-Lopez A, Alastruey-Izquiriedo A, Rodriguez D, Almirante

B, Pahissa A, Rodriguez-Tudela JL, Cuenca-Estrella M., the Barcelona Candidemia Projiect Study Group (2008). Prevalence

and susceptibility profile of Candida metapsilosis and Candida

orthopsilosis: results from population-based surveillance of

candidemia in Spain. Antimicrob. Agents. Chemother. 52:1506-1509.

- Gomez-Lopez A, Pan D, Cuesta I, Alastruey-Izquieerdo A,

Rodriguez-Tudela JL, Cuenca-Estrella M (2010). Molecular

identification and.susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis. 66(1):116-9.

- Gudlaugsson O, Gillespie S, Lee K, et al. (2003). Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 32: 358-66.

- Guinea J, et al., (2006) “Fluconazole resistance mechanisms in

Candida krusei: the contribution of efflus-pumps”, Medical Mycology.

44(6):pp. 575–578.

- Gupta AK, Humke S. (1999). The prevalence and mangement of onychomycosis in diabetic patient.

- Hadfield TL, Smith MB, Vinn Re, et al (1987). Mycoses caused by

Candida lusitaniae. Rev Infec Dis. 9: 1006-1012.

- Hajjeh RA, Sofair AN, Harrison LH, et al. (2004). Incidence of bloodstream infections due to Candida species and in vitro suscettibilies of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 42: 1519-27.

- Hazen, K. C., and S. A. Howell. (2003). Candida, Cryptococcus, and other yeasts of medical importance, p. 1693–1711. In P. R. Murray,

(7)

E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.

- Hensgens LA , Tavanti A, Mogavero S, Ghelardi E, Senesi S. (2009). AFLP genotyping of Candida metapsilosis clinical

isolates:evidence for recombination. Fungal Genet Biol. 46: 750-758.

- Hope W, Morton A, Eisen DP (2002). Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazolo use. J Hosp Infect. 50:56-65.

- Hossein Mirhendi, Brita Bruun,Henrik Carl Schønheyder, Jens

Jørgen Christensen, Kurt Fuursted, Bente Gahrn-Hansen, Helle Krogh Johansen, Lene Nielsen, Jenny Dahl Knudsen and

Maiken Cavling Arendrup. (2009). Molecular screening for

Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a

new RFLP profile for differentiation. Journal of Medical Microbiology. 59, 414–420.

- Julian R. Naglik, George Newport, Theodore C. White,Lynette L. Fernandes-Naglik, John S. Greenspan, Deborah Greenspan, Simon P. Sweet, Stephen J. Challacombe, and Nina Agabian

(1999). In Vivo Analysis of Secreted Aspartyl Proteinase Expression in Human Oral Candidiasis. Infection and Immunity. Vol. 67, No. 5 p. 2482-2490.

- Kao AS, Brandt ME, Pruitt WR, et al. (1999). The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 29: 1164-70.

- Karabinis, A., C. Hill, B. Leclerq, C. Tancrede, D. Baume, and A.

Andremont. (1988). Risck factors for candidemia in carcer patients:

a case-control study. J. Clin. Microbiol. 26: 429-432.

- Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, Mckinsey DS,

Karchmer AW, Sugar AM, et al. (2000). Prospective multicenter

surveillance study of funguria in hospitalized patients. Clin Infec Dis.

30:14-18.

- Kauffman CA. (2001). Fungal infections in older adults. Clin Infect Dis. 33: 550-5.

(8)

- Kevin K. Hazen. New and Emerging Yeasts Pathogens (1995). Clinical Microbiology Reviews. Vol 8, n.4. 462-478.

- Klotz SA, Nguyen HC, Van Pham T, Nguyen LT, Ngo DT, Vu SN

(2007). Clinical feautures of HIV/AIDS patients presenting to an inner city clinic in Ho Chi Minh City, Vietnam. Int J STd AIDS. 18:482-5.

- Kollia K, Velegradi A. (2008). Candidemia. Arch Hellen Med. 25: 41-59.

- Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J,

Hachem R, Bodey GP & Raad II (2001). Risk factors for Candida

tropicalis fungemia in patients with cancer. Clin Infec Dis. 33:

1676-1681.

- Kremery V (1999a) Torulopsis glabrata an emerging yeast pathogen in cancer patients. Int J Antimicrob Agents. 11:1-6.

- Kremery V (1999b) Candidemia in carcer patients: Risk factors and outcome in 140 episodes from a single cancer institution. Acta Chemoth. 5:133-145.

- Kuhn DM, Chandra J, Mukeherjee PK, Ghannoum MA. (2002).

Comparison of biofilms formed by Candida albicans and Candida

parapsilosis on bioprosthetic surfaces. Infect Immun. 70:878-88.

- Kuhn, D. M., and M. A. Ghannoum. (2004). Candida biofilms: antifungal resistance and emergencing therapeutic options. Curr. Opin. Investig. Drugs. 5: 186-197.

- Kuhn, D. M., T. George, j. Chandra, P. K. Mukherjee, and M. A.

Ghannoum. (2002). Antifungal suscetibility of Candida biofilms:

unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.

- Kumarasamy N, Solomon S, Flanigan Tp, Hemalatha R,

Thyagarajan SP, Mayer KH. (2003). Natural history of human

immunodeficiency virus disease in southern India. Clin Infect Dis.

36:79-85.

- Kwon-Chung KJ and Bennett JE (1992). Medical Mycology. Philadelphia: Lea & Febiger.

- L, JR., Jose A. Vazquez, and Jack D. Sobel. (1999). Candida

(9)

Disease with Comparison to C. albicans. Clinical Microbiology Revieuws. Vol.12. N.1; p.80-96.

- Laverdiere M, Rotstein C, Bow EJ, et al. (2000). Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. Canadian Fluconazole Study Group. J Antimicrob Chemother. 46: 1001-8.

- Lockart et al., (2008). Geografic distribution and antifungal suscetipility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related specie

Candida parapsilosis. J. Clin Microbiol. 46:2659-2664.

- Lockart S, Joly S, Vargas K, Swails-Wenger J, Enger L, Soll D. (1999). Natural defendes against Candida colonization breakdown in the oral cavities of the elderly. J Dent Res. 78:857-68.

- Luzzati, R., G. Amalfitano, L. Lazzarini, F. Soldori, S. Bellino, M.

Solbiatic, M.C. Danzi, S. Vento, G. Todeschini, C. Vivenza, and E. Concia. (2000). Nosocomial candidemia in non-neutropenic patients

at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis.

19:602-607.

- M. Bendinelli, C. Chezzi, G. Dettori, N. Manca, G. Morace, L.

Polonelli, M. A. Tufano (2005). Microbiologia medica. Micologia. Gli

agenti infettivi dell’uomo: biologia, azione patogena, laboratorio. Monduzzi Editore.

- Majoros L. et al. (2005). Caspofungin susceptibility testing of Candida incospicua: correlation of different methods with the minimal fungicidal concentration. Antimicrob. Agents. Chemother. 49:3486-3488.

- Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman

CA. (2005). Candida glabrata fungemia:experience in a tertiary care

center. Clin Infec Dis. 41:975-81.

- Marchetti, O., J. Bille, U. Fluckinger, P. Eggimann, C. Ruef, J.

Garbino, T. Calandra, M.P. Glauser, M. G. Tauber, and D. Pittet.

(2004). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38:311-320.

- Marcio Nucci and Kieren A. Marr (2005). Emerging Fungal Diseases. Clinical Infectious Diseases. 41:521–6.

(10)

- Marco F, Lockhart SR, Pfaller MA, et al. (1999). Elucitading the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol. 37:2817-28.

- Marr KA, Seidel K, White TC, Bowden RA. (2000). Candidemia in allogenic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazolo . J Infect Dis.

181:309-16.

- McCarthy KM, Morgan J, Wannemuehler KA, et al. (2006). Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with a hight HIV seroprevalnce. AIDS.

20:2199-206.

- Miranda LN, van der Heijden IM, Costa SF, Sousa AP, Sienra

RA, Gobara S, Santos CR; Lobo RD, Pessoa VP 6 Levin AS.

(2009). Candida colonization as a source for candidemia. J Hosp Infect. 72:9-16.

- Mora-Duarte J. et al.(2002). Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.

- Morgan J, Meltzer MI, Plikaytis BD, et al. (2005). Excess mortality, hospital stay, and cost due to candidemia: a cse-control study using data from population.based candidemia surveillance. Infect Control Hosp epidemiology. 26:540-7.

- Mukherijee, P. K., and J. Chandra. (2004). Candida biofilms resistance. Drug Resist. Updat. 7: 301-309.

- Murray CK, Loo FL, Hospenthal DR, Cancio LC, Jones JA, Kim

SH, et al. (2008). Incidence of systemic fungal infection and related

mortality following severe burns . Burns. 34. 1108-12.

- Myoken, Y., Kyo, T., fujihara, M., Sugata, T. & Mikami, Y. (2004). Clinical significante of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic

malignancies. Haematologica. 89, 378-380.

- National Committee for Clinical laboratory Standards. (2002). Reference method for broth diluition antifungal susceptibility testing of yeasts: approved standard, 2nd ed., M27-A2. National Committee for Clinical laboratory Standards, Wayne, PA.

(11)

- National Committee for Clinical laboratory Standards. (2004). Methods for antifungal disk diffusion susceptibility testing of yeasts: approved guideline, M44-A. National Committee for Clinical laboratory Standards, Wayne, PA.

- Negri M, Martins M, Henriques M, Svidzinski T, Azeredo J &

Oliviera R (2010). Examination of potential virulence factors of

Candida tropicalis clinical isolates from hospitalized patients.

Mycopathologia. 169: 175-182.

- Nielsen H, Stenderup J, Bruun B (1990). Fungemia with

Saccharomycetaceae. Report of four case. Scand J Infect Dis 22: 581-584.

- Odds F. C. et al. (2004). Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and

Aspergillus species. J. Clin. Microbiol. 42:3475-3482.

- Odds FC. (1996). The fungal kingdom: essentials of mycology. In: “Principles and Practice of Clinical Mycology”, Editors Kibbler CC, Mackenzie WR, Odds FC. John Wiley & Sons. Chicester, England.

- Odds, F. C. (1988) Biological aspects of pathogenic Candida spp., p. 7-15. In Candida and candidosis. Bailliere Tindale, London, UK.

- Ostrosky-Zeichner L, Pappas PG. (2006). Invasive candidiasis in the intensive care unit. Crit Care Med. 34:857-63.

- Pappas P.G. et al. (2004). Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38: 161-189.

- Pappas PG, Rex JH, Lee J, et al. (2003). A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 37:634-43.

- Park S. Kelly R. Kahn J.N. Robles J. Hsu M.J. Register E. Li W.

Vyas V. Fan H. Abruzzo G. Flattery A. Gill C. Chrebet G. Parent S.A. Kurtz M. Teppler H. Douglas C.M. Perlin D.S.(2005 ). Specific

substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother.

- Pfaller M. A. (2005). Antifungal susceptibility testing methods. Curr. Drug Targets. 6: 929-94.

(12)

- Pfaller M. A. et al. (2006). Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44:3533-3538.

- Pfaller M. A. et al. (2007). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8,5-years analysis of susceptibilities of Candida species and other yeast specie sto fluconazole and voriconazole detremined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45(6):1735-1745.

- Pfaller M. A. et al. (2007). The epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol. Rev. 20:133-163.

- Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S,

Diekema DJ. (2005). In vitro activities of anidulafungin against more

than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazolo. J Clin Microbiol. 43:5425-7.

- Pfaller MA, Diekema DJ, Rinaldi MG, et al. (2005). Results from the ARTEMIS DISK global antifungal surveeillance study: a 6,5-years analysis of the worldwidw suscetipility of yeasts to fluconazole and voriconazole using standardized disk diffusion testing. J Clin Microbiol. 43: 5848-9.

- Pfaller MA, Diekema DJ. (2002). Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 40: 3551-7.

- Pfaller MA, Diekema DJ. (2004). Rare and emerging opportunist fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 42: 4419-31.

- Pfaller MA, Diekema DJ. (2004). Twelve years of fluconazolo in clinical practice: global trends in species distribution and fluconazolo suscetipility of bloodstreams isolates of Candida. International Fungal Surveillance Participant Group. Cli Microbiol Infect. 10 (Suppl): 11-23.

- Pfaller MA, Diekema DJ. (2005) Unusual fungal and pseudofungal infections of humans. J Clin Microbiol. 43:1495-1504

- Pfaller MA, Diekema DY, Jones RN, Messer SA, Holllis RY. (2002). Trends in antifungal suscetibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections:

(13)

SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 40:852-6.

- Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ,

Diekema DJ. (2004). Geographic variation in the susceptibilities of

invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global asseeement from the ARTEMIS

Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 42:3142-6.

- Pfaller, M. A., and D. J. Diekema. (2007). Azole antifungal drug cross-resistance: mechanism, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74-93.

- Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. (2007). Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796–802.

- Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S.

Tendolkar, and D. J. Diekema. (2008.). In vitro susceptibility of

invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 46:150-156.

- Pfaller, M. A., S. Messer, and R. Hollis. (1994). Genotyping variation, antifungal susceptibility, and slime production among isolates of Candida parapsilosis, abstr. J104, p. 105. In program and abstracts of the 34 th Interscience Conference on Antimicrobial Agents and Chemoterapy. American Society for Microbiology, Washington, D.C.

- Pfaller, M. A.., Boyken, L., Hollis, R. J., Kroeger, j., Messer, S.

A., Tendolkar, S., Diekema, D. J. & ARTEMIS DISK Global Antifungal Surveillance Group (2009). Comparison of results of

fluconazolo and voriconazole disk diffusion testing for Candia spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis. 65, 27-34.

- Poikonen, E., O. Lyytikaninen, V. J. Anttila, and P. Ruutu. (2003). Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 9: 985-990.

(14)

- Polak A. (1990). Mode of action studies. In: Ryley JF, editor. Handbook of Experimental Pharmacology. Vol. 96. heiderberg: Springer-Verlag; pp. 153-82.

- Pruitt BA Jr, McManus AT, Kim SH, et al. (1998). Burn wound infections: Current status. World J Surg. 22:135-145.

- Ramage, G., B. L. Wickes, and J. L. lopez-Ribot. (2001). Biofilms of Candida albicans and their associated resistance to antifungal agents. Am. Clin. Lab. 20: 42-44.

- Ramage, G., S. P. Saville, D. P. Thomas, and J. L. Lopez-Ribot. (2005). Candida biofilms:an update. Eukaryot. Cell. 4: 633-638.

- Range-Frausto, M. S., M. A. Martin, H. Saiman, H. Blumberg, J. E.

Paterson, M. A. Pfaller, R. P. Wenzel, and the NEMIS Study Group. (1994). Hight prevalence of Candida spp. on hands of health

care workers in surgical and neonatal intensive care units, abstr. J106, p.105. In program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemoterapy. American Society for Microbiology, Washington, D.C.

- Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. (1999). National epidemiology of mycoses survey (NEMIS): variations in rates of blood-streams infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 29:253-8.

- Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. (1998). The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population- based laboratory active surveillance. Clin Infect Dis. 27: 1138-47.

- Reingold L, Lu XD, Plikaytis BD, Ajello L. (1986). Syatemic mycoses in the United States, 1980-1982. J Med Vet Mycol. 24:433-6.

- Rex JH and Pfaller MA (2002). Has antifungal suscetibility testing come of age? Clin Infect Dis. 35:982-9

- Richards C, Emori TG, Edwards J, et al. (2001). Characteritics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control. 29:400-403.

(15)

- Richards MJ, Edwards JR, Culver DH, Gaynes RP. (2000). Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol. 21: 510-5.

- Richet, H., P. Roux, C. Des Champs, Y. Esnault, A. Andremont,

and the French Candidemia Study Group. (2002). Candidemia in

Fench hospitals: incidence rates and characteristics. Clin. Microbiol. Infect. 8:405-412.

- Robert B. Ashman and John M. Papadimitriou (1995). Production and Function of Cytokines in Natural and Acquired Immunity to

Candida albicans Infection. Microbiological Reviews. Vol.59. n.4. p

646-672.

- Saiman L, Ludington E, Pfaller M, et al. (2000). Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Disj. 19: 319-24.

- Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., and

Fadda, G. (2004). Mechanisms of azole resistance in clinical isolates

of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 49: 668–679.

- Sarvikivi E, Lyytikainen O, Soll DR, et al. (2005). Emergence of fluconazole resi stance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol.

43:2729-35.

- Schauer, F. and R. Hanschke (1999) Taxonomy and ecology of the genus Candida. Mycoses. 42:12-21.

- Schofield Cm, Murray CK, Horvath EE, Cancio LC, Kim SH, Wolf

Se, et al. (2007). Correlation of culture with histopathology in fungal

burn wound colonization and infection. Burns. 33:341-6.

- Schwacha MG. (2003). Macrophages and post-burn immune dys-function. Burns. 29:1-14.

- Scott. K. Fridkin and William R. Jarvis (1996). Epidemiology of fungal infections. Clinical Microbiology Reviews.Vol 9. 499-511.

- Sean F. Laffey and Geraldine Butler. (2005). Phenotype switching affects biofilm formation by Candida parapsilosis Microbiology. 151, 1073–1081.

(16)

- Seneviratne, C. J., L. Jin, and L. P. Samaranayake, and L.P.

Samaranayake. (2008). Biofilm lifestyle of Candida: a mini review.

Oral Dis. 14:582-590.

- Shin Jk, Kee SJ, Shin MG, et al. (2002). Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstreams isolates with isolates from outher sources. J Clin Microbiol. 40:1244-8.

- Song Jw., Shin Jh., Shint Dh., Jung SI., Cho D., Kee SJ., Shin

MG., Suh SP., Ryang DW. (2005). Differences in biofilm production

by three genotypes of Candida parapsilosis from clinical sources. Med. Mycol. Nov. 43(7):657-61.

- Spelberg B. J. et al. (2006). Current treatment strategies for dissseminated candidiasis. Clin. Infec. Dis. 42:244-251.

- Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T,

Tjoelker R. (1994). High frequency of yeast carriage on hands of

hospital personnel. J Clin Microbiol. 32:2299-300.

- Stuart M. Levitz (1992). Overvieuw of Host Defendes in Fungal Infections. Clinical Infectious Diseases.

- Sulevon et al (1995). Microbiology. 141:1507-1521.

- Tavanti, A., A. Davidson, N. A. R. Gow, M.C.J. Maiden, And, F.C.

Odds (2005) Candida orthopsilosis and Candida metapsilosis,

spp.nov., to Replace Candida parapsilosis groups

II

and

III

. J. Clin. Microbiol. 43:284-292.

- Tavanti, A., L. A. M. Hensgens, E. ghelardi, M. Campa, and S.

Senesi. (2007). Genotyping of Candida orthopsilosis clinical isolates

by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol. 45:1455-1462.

- Tawfik OW, Papasian CJ, Dixon AY, Potter LM (1989).

Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome. J. Clin Microbiol. 27: 1689-1691.

- Tortorano, A. M., E. Biraghi, A. Astofi, C. Ossi, M. Tejada, C.

Farina, S. Perin, C. Bonacccorso, C. Cavanna, A. Raballo, A. Grossi, and the FIMUA Candidemia Stdy Group. (2002).

(17)

survey of candidemia:report from one Italian region. J. Hosp. Infect.

51:297-304.

- Tortorano, A. m., Rigoni, A.L., Biraghi, E., Prigitano, a., Viviani,

M. A. & FIMUA-ECMM Candidemia Study Group (2003). The

European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: antifungal suscetibility patterns of 261

no-albicans Candida isolates from blood. J. Antimicrob Chemother. 52, 679-682.

- Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. (2002). Seculat trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis. 35:627-30.

- Tumbarello L., Posteraro B., Trecarichi EM., Fiori B., Rossi M.,

Porta R., De Gaetano Donati K., La Sorda M., Spanu T., Fadda G., Cauda R., Sanguinetti M. (2007). Biofilm production by Candida

species and inadequate antifungal therapy as predictors of mortality in patients with candidemia. J Clin. Microbiol. Apr 25.

- Van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens D. (2008). Significant differences in drug susecptibility among species in the Candida parapsilosis group. Diagn microbiol Infect Dis. 62.106-109.

- Van Elden lj, Walenkamp AM, Lipovsky MM, et al. (2000). Declining number of patients with cryptococcosis in the Netherlands in the era of highly activa antiretroviral therapy. AIDS. 14:2787-8.

- Vanden Bossche H. (1985). Biochemical targets for antifungal azole derivates: Hypothesis on the mode of action. In: Mc Ginnis MR, editor. Current topics in medical mycology. New York: Springer-Verlag; pp. 313-51.

- Vandewoude KH, Blot SI, Depuydt P, Benoit D, temmerman W,

Colardyn F, et al. (2006). Clinical relevance of Aspergillus isolation

from respiratpry tract samples in critically ill patients. Crit Care.10:R31.

- Varga I, Soczo G, kardos G, Borbely A, Szabo Z, Kemeny-Beke

A, Majoros L. (2008). Comparison of killing activity of caspofungin

against Candida parapsilosis, C. orthopsilosis and C. metapsilosis. J. Antimicrob. Chemother. 62:1466-1468.

(18)

- Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot Jl,

Gobernado M. (2002). Candidemia at a tertiary-care hospital:

epidemiology, treatment, clinical outcome and risk factors for death. Eur J clin Microbiol Infect Dis. 21:767-74.

- Warnock DW. (1991). Amphotericin B: An introduction. J. Antimicrob Chemother. 28:27-38.

- Weems, J. J. J. (1992). Candida parapsilosis: epidemiology, pathogenity, clinical manifestations, and antimicrobial susceptibility. Clin. Infect. Dis. 14: 756-766.

- Wey SB, Mori M, Pfaller Ma, woolson RF, Wenzel RP. (1988). Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern Med; 148:2642-5.

- Wey, S.B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P.

Wenzel. (1989). Risk factors for hospital-acquired candidemia. Arch.

Intern. Med. 149:2349-2353.

- Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney

J. (2002). The direct cost incidence of systemic fungal infections.

Value Health. 5: 26-34.

- Wisplinghoff H, Bischoff T, Tallent SM, et al. (2004). Nosocomial bloodstreams infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis.

39:309-317.

- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP,

Edmond MB. (2004). Nosocomial bloodstream infections in US

hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 39:309-17.

- Yang, Y. L., Ho, Y. A., Cheng, H. H., Ho, M. & Lo, H. J. (2004). Susceptibilities of Candida species to amphotericin B and

fluconazole: the emergence of fluconazole resistance in Candida

tropicalis. Infect Control Hosp Epidemiol. 25, 60-64.

- Zaoutis TE, Argon j, Chu J, Berlin JA, Walsh TJ, Feudtner C. (2005). The epidiemology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 41: 1232-9.